Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

804.24 +21.06 (+2.69%)
Streaming Delayed Price Updated: 11:57 AM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
78 79 Next >
Meet the 5 Stocks That Have Contributed Almost All of the S&P 500's 2024 Gains
These companies have contributed the lion's share of the S&P 500's 7% year-to-date gain. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?
Encouraging results recently pushed the pharma stock up to new heights. 
Via The Motley Fool
Missed Out on Eli Lilly and Novo Nordisk? This Could Be the Next Big Weight Loss Stock.
Viking Therapeutics has a promising anti-obesity treatment that is generating a lot of interest. 
Via The Motley Fool
The Top 3 Pharma Stocks to Buy in March2024
Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge. 
Via InvestorPlace
The Best Stocks to Invest $50,000 in Right Now
These stalwart companies can help you grow your wealth. 
Via The Motley Fool
S&P 500 Soars To New Highs: 5 Best Stocks Ytd
Many semiconductor ETFs also touched new 52-week highs. 
Via Talk Markets
Topics ETFs Stocks
Exposures US Equities
Is Eli Lilly the Best Pharmaceutical Stock for You?
Lilly's recently approved weight-loss drug is off to a good start. 
Via The Motley Fool
In-Depth Analysis: Eli Lilly and Co Versus Competitors In Pharmaceuticals Industry
Via Benzinga
Why Eli Lilly Stock Flopped on Friday
An important new drug's potential approval has been pushed back, and the timing is unclear. 
Via The Motley Fool
Oprah Winfrey To Spotlight Weight Loss Drugs In New TV Special: Will 'Shame, Blame' Come To Drug Companies — Or Could They Get Another Lift?
Weight loss drugs could get an increased spotlight with a television special from legendary TV host Oprah Winfrey. 
Via Benzinga
Novo Nordisk Wins FDA Approval For Obesity Drug, Wegovy, To Cut Cardiovascular Risk
Novo Nordisk stock slumped despite winning FDA approval for its Wegovy in reducing cardiovascular risks. 
Via Investor's Business Daily
Exposures Product Safety
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
BenevolentAI CEO Dr Joerg Moeller discusses AI's impact on drug discovery
--News Direct-- 
Via News Direct
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Stock Market Rally Hits Fresh Highs As Nvidia, Novo Nordisk, Bitcoin Soar: Weekly Review
The Nasdaq and S&P 500 hit new all-time highs. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision
The FDA's upcoming advisory committee meeting on Eli Lilly's Phase 3 donanemab trial for early symptomatic Alzheimer's. Understand safety and efficacy considerations, with a delay in expected FDA... 
Via Benzinga
Exposures Product Safety
FDA Delays Decision On Eli Lilly's Alzheimer Drug
The FDA will hold an advisory panel for Lilly's Alzheimer drug donanemab. 
Via Investor's Business Daily
Exposures Product Safety
Retail Traders Ditch Tesla, Apple, Google For Pharma Stocks Like Ozempic-Maker Novo Nordisk And Eli Lilly: JPMorgan
Retail traders have been observed to be selling off their shares in the 'Magnificent Seven' tech stocks, with a noticeable shift towards pharmaceutical stocks, according to a recent report by... 
Via Benzinga
The Ludicrous List
Essentially the 
Via Talk Markets
3 Stocks Mario Gabelli Is Betting on Big
Given his strong track record, investors should pay attention to these three top-notch Mario Gabelli stocks. 
Via InvestorPlace
Eli Lilly's Legal Battle Against Fake Compounded Tirzepatide Products: Bacteria, Impurities Detected
Discover Eli Lilly's legal action against fraudulent diabetes medication and weight loss treatments. Learn about impurity levels and bacterial concerns. 
Via Benzinga
The Top 3 ETFs to Buy in March 2024
Simplify your investment strategy through these top ETFs to buy, offering an excellent blend of diversification and upside. 
Via InvestorPlace
Topics ETFs
Insurance Coverage For Weight Loss Drugs - Cigna Unveils Efforts To Limit Health Plans/Employers Spending
Evernorth Health Services, a Cigna subsidiary, introduces a financial guarantee in its EncircleRx program offering predictability for employers and health plans. Highlights agreements with Novo Nordisk... 
Via Benzinga
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,... 
Via Benzinga
Novo Nordisk's Stock Hits 52-Week High After Highly Sought After Obesity Drug Trial Data
Explore Novo Nordisk's Capital Markets Day insights! Uncover early trial success of amycretin, a potential obesity drug, with 13.1% weight loss in Phase 1. Learn about its safety and upcoming Phase 2... 
Via Benzinga
Novo Nordisk Jumps On Strong Results For New Weight-Loss Drug
Amycretin showed a 13.1% weight loss after 12 weeks in a phase 1 trial. 
Via Investor's Business Daily
Why Meta Platforms Stock Topped the Market Today
Investors were happy that the company had a generally uneventful Wednesday. 
Via The Motley Fool
Trillion-Dollar Threshold: The Next 3 Stocks Ready to Rise
With a trillion-dollar valuation in sight, these three growth companies have stocks ready to rise to meet the challenge. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Dexcom — And The Obesity Market — Could Benefit From This New FDA Win
The FDA granted Dexcom's Stelo a broad clearance, meaning people without diabetes can use it. 
Via Investor's Business Daily
Exposures Product Safety
Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk
Eli Lilly's strategic collaborations with outsourcing partners for Zepbound (tirzepatide) production. Challenges persist as Eli Lilly and Novo Nordisk address production bottlenecks amid rising... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
78 79 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.